Loading stock data…
AMLX
$13.39-0.16 (-1.18%)
Market OpenUpdated 2:53 PM EDT
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Amylyx Pharmaceuticals, Inc. in the Healthcare sector is trading at $13.39. Wall Street consensus targets $23.40 (10 analysts), implying a +74.8% move over the next 12 months. The stock is currently 28% below its 52-week high of $18.61, remaining 3.6% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +74.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$43.78M↓ | -$36.60M↓ | -$36.03M↑ | -$42.86M↓ | -$37.80M |
| Net Income | -$41.28M↓ | -$33.00M↑ | -$34.39M↑ | -$41.44M↓ | -$35.91M |
Peer Comparison
JNJUNHPFE
Fundamentals
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigation...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-54.95%
Volume
Today's trading volume
460,202
Recent News
A Look At Amylyx Pharmaceuticals (AMLX) Valuation After Its Recent Share Price Rebound
Why Amylyx Pharmaceuticals (AMLX) Is Drawing Attention Now Amylyx Pharmaceuticals (AMLX) is back on many investors’ radars after recent trading, as the stock’s mixed near term performance contrasts with its longer term returns and current valuation metrics. See our latest analysis for Amylyx Pharmaceuticals. At a recent share price of US$14.35, Amylyx Pharmaceuticals has seen its 7 day share price return of 5.67% partly offset the 10.37% decline over 30 days. The 1 year total shareholder...
Amylyx Stock: Why the Full Pipeline Story Matters
Amylyx stock has surged on pipeline progress, but investors should understand the risks and long-term catalysts driving AMLX shares
Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 2026 Results and Pipeline Progress
We recently compiled a list of the 8 Best Small Cap Pharma Stocks to Buy Right Now. Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is among the best pharmaceutical stocks. TheFly reported on May 7 that AMLX reported first-quarter 2026 results for the period ended March 31, 2026, alongside pipeline and clinical updates. R&D expenses rose to $27.6 […]
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares
This clinical-stage biotech develops therapies for rare muscle diseases, leveraging its FORCE platform to target significant unmet needs.
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors
Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions.